Improving cognition through telehealth exercise and cognitive training for first-episode schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to enhance cognitive function in individuals experiencing their first episode of schizophrenia by combining telehealth-delivered aerobic exercise with cognitive training. Participants will be randomly assigned to either an aerobic exercise and strength training group or a Healthy Living Group, both receiving cognitive training over a 12-month period. The study will measure improvements in cognition, engagement in exercise sessions, and levels of brain-derived neurotrophic factor (BDNF) to assess the effectiveness of the interventions. The use of videoconferencing for delivery aims to demonstrate the feasibility of this approach outside of traditional academic settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. a first episode of a psychotic illness that began within the past three years;
2. a diagnosis by DSM-5 of schizophrenia, schizoaffective disorder, or schizophreniform disorder;
3. age 18 to 45 years of age;
4. sufficient acculturation and fluency in the English language to avoid invalidating research measures; and
5. residence likely to be within commuting distance of the UCLA Aftercare Research Program.

Exclusion Criteria:

1. premorbid IQ less than 70;
2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury;
3. evidence of moderate or severe substance use disorder within the six months prior to the first episode or evidence of a substance-induced psychosis.

Where it's running

• UCLA Aftercare Research Program
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Keith H Nuechterlein, PhD — University of California, Los Angeles
• Study coordinator: Danielle Denenny, PhD
• Email: Ddenenny@mednet.ucla.edu
• Phone: (323) 475-8252

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Brain-derived miRNA biomarkers in first-episode psychosis

  Researchers will test whether specific brain-derived microRNAs in blood can help identify schizophrenia early and track treatment in people with first-episode psychosis on aripiprazole or risperidone.

  Recruiting Northwell Health · Glen Oaks, New York · NCT07703670

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

• Cognitive Strategies in Early Psychosis 2 – how brain games and pills test decision making

  This study tests whether a single dose of modafinil or d-serine, compared with placebo, changes decision making in people aged 18–35 who have recently begun experiencing psychosis.

  Recruiting Phase 3 University of Minnesota · Minneapolis, Minnesota · NCT07263022

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.